Abstract: The present invention describes IL-1? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1?. Binding proteins of the invention have high affinity for IL-1? and neutralize IL-1? activity. A binding protein of the invention can be a full-length antibody or an IL-1?-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1? binding proteins of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, including in a human subject suffering from a disease or disorder in which IL-1? activity is detrimental.
Type:
Grant
Filed:
October 15, 2010
Date of Patent:
March 19, 2013
Assignee:
AbbVie Inc.
Inventors:
Chengbin Wu, Chung-ming Hsieh, Renee Miller, Dominic J. Ambrosi
Abstract: Provided are assays to measure the presence and quantity of an antibody of interest in a patient's bloodstream or other biological sample. ECL and ELISA methods, and kits for such assays, as well as anti-idiotypic antibodies provided to detect levels of the antibody in biological samples, which are from, for example, animal models and human patients.
Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
Type:
Grant
Filed:
May 17, 2011
Date of Patent:
February 19, 2013
Assignee:
Xoma Technology Ltd.
Inventors:
Linda Masat, Mary Haak-Frendscho, Gang Chen, Arnold Horwitz, Marina Roell
Abstract: Antibodies that which specifically bind to mammalian cytokine-like polypeptide, called Zcyto10, are described. The antibodies include monoclonal antibodies and those that where the antibody is an antigen-binding fragment. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.
Type:
Grant
Filed:
January 30, 2012
Date of Patent:
February 19, 2013
Assignee:
ZymoGenetics, Inc.
Inventors:
Darrell C. Conklin, Betty A. Haldeman, Angelika Grossman
Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
Abstract: Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment of an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form.
Abstract: The present invention relates to methods for preventing or treating toxicities associated with exposure to ionizing radiation or to chemotherapy. Particularly, the present invention relates to methods for preventing or treating toxicities associated with radiation or chemotherapy comprising administering to a subject in need of such treatment polypeptide complexes comprising an IL-6 linked to a soluble IL-6 receptor, the polypeptide complexes capable of preventing or treating toxicities, particularly xerostomia.
Type:
Grant
Filed:
November 27, 2008
Date of Patent:
February 12, 2013
Assignees:
Hadasit Medical Research Services and Development Ltd., Christian-Albrechts-Universitat Zu Kiel
Inventors:
Jonathan H. Axelrod, Eithan Galun, Stefan Rose-John, Ytzhack Marmary
Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
Abstract: Use of IL-6 for treating non-hematopoietic cancers, e.g., gp130-negative cancers. Also disclosed is a method for identifying a cancer patient suitable for the IL-6 treatment.
Abstract: The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient for diagnostic purposes, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of procalcitonin, or procalcitonin partial peptides derived therefrom, having the amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116 (SEQ ID NO: 1.) Also disclosed are antibodies and kits for carrying out such a method.
Abstract: The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2R?). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2? using yeast surface display to generate mutants with increased affinity for IL-2R?.
Type:
Grant
Filed:
April 15, 2011
Date of Patent:
January 8, 2013
Assignee:
Massachusetts Institute of Technology
Inventors:
Karl Dane Wittrup, Balaji M. Rao, Douglas A. Lauffenburger
Abstract: Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
Type:
Grant
Filed:
April 23, 2012
Date of Patent:
January 1, 2013
Assignee:
Schering Corporation
Inventors:
Gerard T. Hardiman, Devora L. Rossi, Kevin B. Bacon, J. Fernando Bazan, Thomas J. Schall, Albert Zlotnik
Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.
Type:
Grant
Filed:
July 21, 2008
Date of Patent:
December 25, 2012
Assignee:
Protaffin Biotechnologie AG
Inventors:
Andreas Kungl, Anna Maria Piccinini, Christian Weber
Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
Type:
Grant
Filed:
September 7, 2011
Date of Patent:
December 25, 2012
Assignee:
NovImmune S.A.
Inventors:
Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriatic arthritis.
Type:
Grant
Filed:
November 18, 2011
Date of Patent:
December 11, 2012
Assignee:
Janssen Biotech, Inc.
Inventors:
Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriasis.
Type:
Grant
Filed:
November 18, 2011
Date of Patent:
December 11, 2012
Assignee:
Janssen Biotech, Inc.
Inventors:
Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
Abstract: An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1?/CCL3, MIP-1?/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
Abstract: An isolated recombinant polypeptide having myostatin antagonist activity, comprising a C-terminally truncated mature myostatin peptide, wherein the C-terminal truncation is at a position at or between amino acids 281 and 329, or a fragment, variant or derivative thereof.
Type:
Grant
Filed:
August 2, 2007
Date of Patent:
November 13, 2012
Assignee:
Myostin Therapeutics Pty Ltd.
Inventors:
Ravi Kambadur, Mridula Sharma, Monica Senna Salerno De Moura, Carole J. Berry, Victoria Siriett, Robert Syndecombe Bower, Gina Diane Nicholas, Craig Desmond McFarlane